B-CELL LYMPHOMA REFRACTORY
Clinical trials for B-CELL LYMPHOMA REFRACTORY explained in plain language.
Never miss a new study
Get alerted when new B-CELL LYMPHOMA REFRACTORY trials appear
Sign up with your email to follow new studies for B-CELL LYMPHOMA REFRACTORY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for brain lymphoma: drug combo targets tough cases
Disease control Recruiting nowThis study tests a drug called selinexor combined with chemotherapy in 37 adults with B-cell lymphoma that has come back or not responded to treatment and has spread to the brain. The goal is to find the safest dose and see if the combination can shrink tumors. Selinexor works by…
Matched conditions: B-CELL LYMPHOMA REFRACTORY
Phase: PHASE1, PHASE2 • Sponsor: Samsung Medical Center • Aim: Disease control
Last updated Jun 23, 2026 11:59 UTC
-
Engineered immune cells take on Hard-to-Treat blood cancers
Disease control Recruiting nowThis early-phase study tests a personalized therapy where a patient's own immune cells are modified to recognize and attack cancer cells. It is for children and adults with certain blood cancers (like leukemia or lymphoma) that have not responded to standard treatments. The goal …
Matched conditions: B-CELL LYMPHOMA REFRACTORY
Phase: PHASE1 • Sponsor: Nelson Hamerschlak • Aim: Disease control
Last updated Jun 22, 2026 12:08 UTC
-
New CAR T-Cell therapy offers hope for Tough-to-Treat lymphoma
Disease control Recruiting nowThis study tests a new type of CAR T-cell therapy for people with B-cell lymphoma that has returned or not responded to standard treatments. About 30 participants will receive immune cells that are specially trained to attack their cancer. The goal is to find the best dose and se…
Matched conditions: B-CELL LYMPHOMA REFRACTORY
Phase: PHASE1, PHASE2 • Sponsor: National University Hospital, Singapore • Aim: Disease control
Last updated Jun 17, 2026 12:08 UTC
-
New mRNA CAR-T therapy aims to tackle tough blood cancers
Disease control Recruiting nowThis study tests a new type of CAR-T cell therapy that uses mRNA to target two proteins (CD19 and CD20) on cancer cells. It is for people with B-cell lymphoma or leukemia that has come back or not responded to treatment. The goal is to see if it is safe and effective, with up to …
Matched conditions: B-CELL LYMPHOMA REFRACTORY
Phase: PHASE2 • Sponsor: Daihong Liu • Aim: Disease control
Last updated Jun 11, 2026 12:10 UTC